Yair Einhorn - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Yair Einhorn

Yair Einhorn

Creator
0 followers

Biotech and pharma commentator; focuses on gene editing, CRISPR and biotech market analysis for investors.

Recent Posts

Weekly BioTech Roundup: Top Posts Curated by BiopharmIQ
Social•Feb 21, 2026

Weekly BioTech Roundup: Top Posts Curated by BiopharmIQ

Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏 BioTwitter accounts - all into one place. Do give him a follow. $XBI

By Yair Einhorn
FDA Cracks Down as Novo Sues Hims over Semaglutide
Social•Feb 20, 2026

FDA Cracks Down as Novo Sues Hims over Semaglutide

This is the first reference which I heard directly from FDA commissioner Dr. Marty Makary regarding $HIMS, $NVO 🧵👇and the recent legal actions that the HHS had initiated against HIMs and Hers. When he was asked by @annikakimc - @CNBC’s...

By Yair Einhorn
Must‑Follow BioTech & Finance Accounts for Creators
Social•Feb 13, 2026

Must‑Follow BioTech & Finance Accounts for Creators

Part of being a content creator on 𝕏 should be to promote other valuable creators as much as possible. So, here is a list of top tier accounts who create exceptional content & who are A MUST FOLLOW in BioTech...

By Yair Einhorn
CRISPRTX Unveils 2026 Roadmap: In‑Vivo
Social•Jan 19, 2026

CRISPRTX Unveils 2026 Roadmap: In‑Vivo

1/@CRISPRTX recent #JPM26 presentation emphasised the company’s strategic priorities and planned milestones for 2026. Here’s my 🧵👇which focuses on CRISPR’s In-Vivo and siRNA extended pipeline, the progress of CASGEVY’s launch and $CRSP current corporate status. $XBI #JPM2026 https://t.co/octkTAE5h4

By Yair Einhorn
Top JPM26 Highlights: Weekly BioTech Recap
Social•Jan 16, 2026

Top JPM26 Highlights: Weekly BioTech Recap

Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ, which is a comprehensive recap of the past week in BioTech. This time he gathered the best posts - written by some of the brightest BioX accounts, about...

By Yair Einhorn
BiotechCH's Space: Must‑Watch for BioTech & Pharma Enthusiasts
Social•Jan 16, 2026

BiotechCH's Space: Must‑Watch for BioTech & Pharma Enthusiasts

I highly recommend attending @BiotechCH’s upcoming space today - which in my opinion is the most interesting space on 𝕏 for those interested in BioTech, Pharma, Life Sciences & everything in between….If you can’t attend it’s also available on the...

By Yair Einhorn
Poll: Which Company Should I Thread Next?
Social•Jan 15, 2026

Poll: Which Company Should I Thread Next?

So far I have finished writing two comprehensive 🧵which covered both $BEAM & $PRME #JPM26’s presentations. $XBI Before I continue to write additional #JPM2026🧵’s I’m interested in hearing your thoughts about which company - if at all - would you want...

By Yair Einhorn
BeamTx Unveils 2026 Roadmap and FDA Wins
Social•Jan 13, 2026

BeamTx Unveils 2026 Roadmap and FDA Wins

1/@BeamTx’s #JPM26 excellent presentation emphasised its strategic priorities & future milestones for 2026. Here’s my🧵👇which elaborates on BEAM’s current pipeline, the regulatory breakthroughs that $BEAM has managed to negotiate with the FDA & its corporate status $XBI #JPM2026 https://t.co/kK7Q1YVjOV

By Yair Einhorn